Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement
Newcastle University ePrints (Newcastle Univesity) · 01.03.2023
DOI: 10.25405/ncl.34452180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Newcastle University ePrints (Newcastle Univesity), erschienen am 01.03.2023. Verfasst von Simon N. Bomken und 39 weiteren Autor:innen.
Abstract (Originalsprache)
Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) carries an immunoglobulin-MYC rearrangement (IG-MYC-r). This can result in diagnostic confusion with Burkitt lymphoma/leukaemia and use of unproven individualised treatment schedules. Here we contrast the molecular characteristics of these conditions and investigate historic clinical outcome data.We identified 90 cases registered on a national BCP-ALL clinical trial/registry. Where present, diagnostic material underwent cytogenetic, exome, methylome and transcriptome analysis. Outcome was analysed to define 3-year event free survival (EFS) and overall survival (OS).IG-MYC-r was identified in diverse cytogenetic backgrounds, co-existing with either: established BCP-ALL specific abnormalities (high hyperdiploidy n=3, KMT2A-rearrangement n=6, iAMP21 n=1, BCR-ABL n=1); BCL2/BCL6-rearrangements (n=15); or, most commonly, as the only defining feature (n=64). Within this final group, precursor-like V(D)J breakpoints predominated (8/9) and KRAS mutations were common (5/11). DNA methylation identified a cluster of V(D)J rearranged cases, clearly distinct from Burkitt leukaemia/lymphoma. Children with IG-MYC-r within that subgroup had 3-year EFS of 47% and OS of 60%, representing a high-risk BCP-ALL. To develop effective management strategies this patient group must be allowed access to contemporary, minimal residual disease adapted, prospective clinical trial protocols.
Zitieren
APA
Bomken, S. N., Enshaei, A., Schwalbe, E., Mikulasova, A., Dai, Y., Zaka, M., Fung, K., Bashton, M., Lim, H., Jones, L., Karataraki, N., Winterman, E., Ashby, C., Attarbaschi, A., Bertrand, Y., Bradtke, J., Buldini, B., Burke, G. A., Cazzaniga, G., …, & Russell, L. J. (2023). Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement. Newcastle University ePrints (Newcastle Univesity). https://doi.org/10.25405/ncl.34452180
Vancouver
Bomken SN, Enshaei A, Schwalbe E, Mikulasova A, Dai Y, Zaka M, et al. Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement. Newcastle University ePrints (Newcastle Univesity). 2023. doi:10.25405/ncl.34452180
BibTeX
@article{Bomken2023,
author = {Bomken, Simon N. and Enshaei, Amir and Schwalbe, Edward and Mikulasova, A and Dai, Y and Zaka, M and Fung, KTM and Bashton, Matthew and Lim, HK and Jones, L and Karataraki, Nefeli and Winterman, E and Ashby, C and Attarbaschi, A and Bertrand, Y and Bradtke, J and Buldini, B and Burke, G. A.Amos and Cazzaniga, G and Gohring, G and Groot-Kruseman, HA De and Haferlach, C and Nigro, L Lo and Parihar, M and Plesa, A and Seaford, E and Sonneveld, E and Strehl, S and Velden, V van der and Rand, Vikki and Hunger, SP and Harrison, C. M. and Bacon, Chris M. and Delft, Frederik W. van and Loh, M and Moppett, J and Vormoor, J and Walker, BA and Moorman, Anthony V. and Russell, Lisa Jane},
title = {Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement},
journal = {Newcastle University ePrints (Newcastle Univesity)},
year = {2023},
doi = {10.25405/ncl.34452180}
}
EUVIMED